VDA-1275 is a potent small molecule new chemical entity (NCE) with novel mechanism of action that selectively modulates VDAC/HK2 interaction. It is highly potent in vitro against a broad range of tumor types and demonstrates significant selectivity for VDAC/HK2 system over VDAC/HK1 system. VDA-1275 is chemically unrelated to VDA-1102, and presents a different set of pharmacokinetic characteristics.
VDA-1275 is being developed as a systemic drug for treatment of solid tumors.
